← All Conmed CORP filings

Conmed CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NYSE
CNMD
Conmed CORP
DEF: CONMED's 2025 Strategic Shift: Growth, Buyback, Dividend Cut
CONMED's 2026 proxy statement reveals 5.2% revenue growth in 2025, a dividend suspension, a $150M share repurchase, and significant board and executive leadership transitions.
NYSE
CNMD
Conmed CORP
DEFA14A: CONMED Addresses Stockholder Concerns Over Dilution in 2025 Long-Term Incentive Plan
CONMED provides additional details on its equity strategy, emphasizing its reliance on stock options and adjusted dilution levels, to garner support for the 2025 Long-Term Incentive Plan.
NYSE
CNMD
Conmed CORP
DEFA14A: CONMED Corporation Announces Annual Meeting of Stockholders
CONMED Corporation will hold its annual meeting of stockholders on May 20, 2025, to vote on key proposals including the election of directors, executive compensation, and the ratification of the company's auditor.
NYSE
CNMD
Conmed CORP
DEF 14A: CONMED Corporation Announces CEO Succession, Board Refreshment, and Strategic Focus for 2025
CONMED Corporation's proxy statement highlights a CEO transition, board changes, and strategic priorities for 2025, including resolving supply chain issues and focusing on high-growth platforms.
NYSE
CNMD
Conmed CORP
DEFA14A: CONMED Corporation to Hold Annual Meeting of Stockholders on May 22, 2024
CONMED Corporation will hold its annual meeting of stockholders on May 22, 2024, to elect directors, conduct an advisory vote on executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as its independent auditor.
NYSE
CNMD
Conmed CORP
DEF 14A: CONMED Corporation Announces Details for 2024 Annual Meeting of Stockholders
CONMED Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, executive compensation, and auditor ratification.